KYTRIL TABLETS 1MG

Land: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

GRANISETRON (GRANISETRON HYDROCHLORIDE)

Fáanlegur frá:

HOFFMANN-LA ROCHE LIMITED

ATC númer:

A04AA02

INN (Alþjóðlegt nafn):

GRANISETRON

Skammtar:

1MG

Lyfjaform:

TABLET

Samsetning:

GRANISETRON (GRANISETRON HYDROCHLORIDE) 1MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

2/10

Gerð lyfseðils:

Prescription

Lækningarsvæði:

5-HT3 RECEPTOR ANTAGONISTS

Vörulýsing:

Active ingredient group (AIG) number: 0123183001; AHFS:

Leyfisstaða:

CANCELLED POST MARKET

Leyfisdagur:

2015-11-06

Vara einkenni

_Page 1 of 27 _
_ _
_ _
PRODUCT MONOGRAPH
Pr
KYTRIL
®
granisetron hydrochloride tablets
1 mg granisetron as hydrochloride
MANUFACTURE STANDARD
Antiemetic
(5-HT
3
receptor antagonist)
Hoffmann-La Roche Limited
Date of Revision:
7070 Mississauga Road
June 6, 2014
Mississauga, Ontario
L5N 5M8
www.rochecanada.com
©Copyright 2001 – 2014 by Hoffmann-La Roche Limited.
Control No. 172914
®KYTRIL is a registered trade-mark of F. Hoffmann-La Roche AG, used
under license.
_Page 2 of 27 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICA